Drug Profile
Baloxavir marboxil - Roche/Shionogi
Alternative Names: RG 6152; RG 6152-1; S 033188; XOFLUZA; XofluzaLatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Shionogi
- Developer Roche; Shionogi
- Class Antivirals; Dibenzothiepins; Esters; Morpholines; Pyridines; Small molecules; Triazines
- Mechanism of Action Endonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza A virus infections; Influenza B virus infections; Influenza virus infections
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 15 Feb 2024 Roche plans regulatory filing for Influenza virus infection (direct transmission) in 2024 (Roche pipeline, February 2024)
- 15 Nov 2023 Hoffmann-La Roche initiates a phase IIIb Pebblestone trial in Influenza (In children) in USA (PO) (NCT06094010)
- 21 Aug 2023 Roche plans regulatory filing for Influenza virus infection (In Infants) in 2024 (Roche pipeline, August 2023)